ADC Space Continues to Thrive with Four More Companies Linking Up

As antibody-drug conjugates (ADCs) continue to show their potential, four more biopharma companies entered into partnerships this week to combine their respective expertise.

California-based Exelixis, Inc. and Swedish company BioInvent International AB, announced Thursday that they have entered into an option and license agreement to discover and develop novel antibodies for immuno-oncology therapeutics.